Sofinnova closes its largest fund at €725 million for European biotech
Sofinnova Partners has closed its largest fund to date, raising €725 million for Crossover II, which will back about 15 primarily European clinical-stage biotech and medical-device companies preparing to commercialize or expand globally. The fund has already invested in Hemab Therapeutics, CellCentric and Neurent Medical, and will selectively consider companies in the United States and other markets. Sofinnova says it will provide active support on areas including leadership, clinical trials and public listings, targeting businesses with promising clinical evidence and the potential to become global leaders. The raise comes amid concern that European life sciences companies face a shortage of growth capital despite the region’s strong scientific base.







